10 Most Profitable Undervalued Stocks to Buy

2. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 76

Forward PE: 10.06x

ROE: 33.84%

On February 6, 2026, Guggenheim raised its price target on Bristol-Myers Squibb Company (NYSE:BMY) to $72 from $62 and reiterated a Buy rating. The firm significantly increased its estimated probability of success for iber/mezi to 90% from 33% and lifted its success odds for milvexian in SSP to 90% from 75%. Guggenheim said it continues to recommend buying the shares ahead of what it described as a series of high-profile, potentially high-reward Phase 3 catalysts.

Several other firms also updated their views following BMY’s earnings report.

Bank of America also updated its view on February 6, 2026, raising its price target to $68 from $64 while maintaining a Buy rating. The firm increased near-term forecasts following fourth-quarter results and fiscal 2026 guidance that came in ahead of expectations. BofA framed Bristol Myers as a pipeline-driven story and said Q4 commentary was supportive for several programs where safety had been an open question. The firm added that positive Phase 3 read-across from Bayer’s SSP data helps derisk the opportunity for milvexian.

Wells Fargo analyst Mohit Bansal raised his price target to $60 from $55 the same day while keeping an Equal Weight rating. Wells Fargo sees potential upside to 2026 guidance if the growth portfolio outperforms current mid-single-digit assumptions. With guidance now set, the firm said investor focus is likely to shift toward upcoming pipeline readouts in 2026, including CelMoDs, LPA1, milvexian, and Cobenfy.

Citi also weighed in on February 6, lifting its price target to $64 from $60 while reiterating a Neutral rating. The firm described fourth-quarter results as strong but said future share upside will hinge largely on pipeline execution and clinical wins.

Bristol Myers reported fourth-quarter revenue of $12.5 billion on February 5, 2026, topping the $12.28 billion consensus estimate. CEO Christopher Boerner said the company exited 2025 with momentum in its growth portfolio and a strengthened balance sheet, adding that 2026 is expected to be data-rich, with multiple pivotal pipeline readouts anticipated in the back half of the year.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.